Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study

Uçan et al., Research Square, doi:10.21203/rs.3.rs-175340/v1
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV, however the groups are not comparable and no adjustments were made. FPV was first used in patients whose clinical condition worsened or whose pneumonia findings progressed, while later patients started FPV treatment early.
Uçan et al., 4 Feb 2021, retrospective, Turkey, preprint, 8 authors, average treatment delay 4.73 days.
This PaperFavipiravirAll
Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Anıl Uçan, Pamir Çerçi, Serdar Efe, Hakan Akgün, Ahmet Özmen, Aysel Yağmuroğlu, Muzaffer Bilgin, Deniz Avcı
doi:10.21203/rs.3.rs-175340/v1
Background: Although more than a year past since COVID-19 was de ned, there is no speci c treatment yet. Since COVID-19 management differs over time, it is hard to determine which therapy is more e cacious. In this study, we aimed to evaluate the e cacy of the regimen with Favipiravir (FPV) and determine if the timing of FPV addition offers any improvement. Methods: A retrospective observational case-controlled cohort study was performed between March and Sep-tember 2020, including adults with COVID-19 in a single-center in Turkey. We categorized patients into age-sex matched three groups, group 1 (n=48) and group 2 (n=48) included patients treated with the combination of FPV plus Hydroxychloroquine (HQ) early and late, respectively. Group 3 (n=48) consisted of patients on HQ monot-herapy. In Group 2, if the respiratory or clinic condition had not improved su ciently, FPV was added on or after day 3. Results: We found that starting FPV early had an impact on PCR negativity and the progression of the disease. 'No progression' was de ned as the absence of a new nding in the control radiological examination and the absence of accompanying clinical deterioration. Also, the decrease in C-reactive protein (CRP) was greater in Group 1 than Group 3 (p <0.001). However, we found that early initiation of FPV treatment did not have a posi-tive effect on the estimated survival time. Conclusions: According to this retrospective study results, we believe that for better clinical outcomes, FPV treatment should be started promptly to enhance antiviral effects and improve clinical outcomes.
Declarations Authors' contributions AU and PC contributed to the study conception and design. Data collection, material preparation, and analysis were performed by SE, AY, HA, and AO. All authors commented on the latest version of the manuscript, and all authors read and approved the nal manuscript. Consent for publication Not applicable. Competing Interests The authors declare that they have no competing inte rests.
References
Bai, Mu, Kargbo, Song Y Bin, Niu et al., Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with Favipiravir (T-705) -Sierra Leone, Clin Infect Dis
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Eng
Casas-Rojo, Santos, Millán-Núñez-Cortés, Lumbreras-Bermejo, Ramos-Rincón et al., Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry, Rev Clínica Española (English Ed
Chen, Huang, Yin, Zhang, Cheng et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, doi:10.1101/2020.03.17.20037432
Chen, Wang, Lin, Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia, Clin Toxicol
Chu, Cheng, Hung, Wong, Chan et al., Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical ndings, Thorax
Du, Chen, Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection, Clin Pharmacol Ther, doi:10.1002/cpt.1844
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy Series B: Physical and Biological Sciences
Grasselli, Pesenti, Cecconi, Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy, JAMA
Guan, Liang, Zhao, Liang, Chen et al., Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis, Eur Respir J, doi:10.1183/13993003.00547-2020
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Lagadinou, Salomou, Zareifopoulos, Marangos, Gogos et al., Prognosis of COVID-19: Changes in laboratory parameters, Le Infez Med
Lauer, Grantz, Bi, Jones, Zheng et al., The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported con rmed cases: Estimation and application, Ann Intern Med [Internet, doi:10.7326/M20-0504
Li, Clercq, Therapeutic options for the 2019 novel coronavirus
Organization, Clinical management of COVID-19: interim guidance
Pourbagheri-Sigaroodi, Bashash, Fateh, Abolghasemi, Laboratory ndings in COVID-19 diagnosis and prognosis, Clinica Chimica Acta. Elsevier B.V
Prokop, Van Everdingen, Rees Vellinga, Van Ufford, Stöger et al., CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-De nition and Evaluation, Radiology
Shiraki, Daikoku, Favipiravir, an anti-in uenza drug against life-threatening RNA virus infections
Sissoko, Laouenan, Folkesson, Lebing, Beavogui et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med
Team, Team, The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China, China CDC Weekly
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA -J Am Med Assoc
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit